Biomarker family found for chemo resistant breast cancers

Biomarkers which could help to predict resistance to chemotherapy in breast cancer patients have been identified by researchers from the University of Hull, UK.

The researchers found a family of proteins to be twice as prevalent in clinical samples obtained from who were resistant to chemotherapy than those who were successfully treated.

Chemotherapy resistance is a major problem for some types of and many patients undergo treatment that does not work, delaying other more suitable treatments and subjecting the patient to adverse side effects in the process.

Published online in the Journal of Proteomics, the Hull research identifies a number of potential biomarkers associated with resistance to common , including epirubicin and .

Lead researcher Dr Lynn Cawkwell, says: "A major goal in cancer research is to be able to predict the response of a patient to chemotherapy. Unfortunately, a reliable test has not yet been developed to achieve this. We hope our work can help to bring us a step closer.

"Most of my work uses clinical samples instead of cell lines, thanks to the links I have with oncologists and surgeons at Castle Hill Hospital in Hull. Studying clinical samples gives a more accurate representation of what is relevant in real-life diseases."

The project used two high-throughput processes to screen clinical samples of breast tumour tissue.

One screening method using antibodies identified 38 proteins that were twice as prevalent in samples from patients who were resistant to chemotherapy than those who were successfully treated. The other used and uncovered 57 potential biomarkers of which five belong to the 14-3-3 .

The findings from both screening methods highlight the possible importance of proteins from the 14-3-3 family and their potential for development into a predictive test for clinical use. Dr Cawkwell's team hope to investigate the protein family's role more fully in chemotherapy resistance.

"If we're correct, we hope that by testing for these proteins, doctors will be able to anticipate a patient's response to different chemotherapies, and decide which course of treatment is most appropriate for them," she says.

Dr Cawkwell's team is continuing with this study, as well as investigating radiotherapy resistance in a number of different cancers.

More information: J Proteomics 2012 April 3 [epub ahead of print] Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer

J Proteomics. 2012 Feb 2;75(4):1276-83 Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID? Hodgkinson VC, Elfadl D, Agarwal V, Garimella V, Russell C, Long ED, Fox JN, McManus PL, Mahapatra TK, Kneeshaw PJ, Drew PJ, Lind MJ, Cawkwell L.

Related Stories

Recommended for you

Psychologists aim to help Dr Google

date 10 hours ago

Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek help.

New method detects more breast cancer in screening

date 14 hours ago

Tomosynthesis detects 40% more breast cancers than traditional mammography does, according to a major screening study from Lund University, Sweden. This is the first large-scale study to compare the screening ...

Women's use of talc powder may be tied to ovarian cancer

date May 05, 2015

Deane Berg's doctor called her in the day after Christmas 2006 to give her the crushing news. She'd had her ovaries removed, the pathology results were back, and the information could not have been much worse. Berg had stage ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.